Corona Remedies Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/l5sxq5xtayy02fvt9y3fnmxn.pdf

Key Takeaways


Revenue Growth & Volume Story

Nirav Mehta: “So, you know, nobody knows the reason, to be very honest. We are just predicting that this may be one of the reasons. So I am not an expert to comment on this, but I am expecting that IPM will continue to grow on 10%, at least in a quarter to come, looking at the current momentum.”

Engine Brands & Portfolio Strategy

Nirav Mehta: “If we ever sell and we don't have a brand, I think we are in the wrong business if you talk about IPM and sustainable growth.”

Wokadine & IVF Task Force

Nirav Mehta: “The integration and change in business model are a little slower than expected. But the next 2 quarters will give us more visibility. We are still very confident in achieving 25% CAGR for Wokadine over 3 to 4 years.”

International Business


Margins & Profitability


New Therapy Entry & M&A

Nirav Mehta: “We never try to think about the multiples which we are giving. We always try to calculate what we are going to gain from it and how our business model looks, how we plan to take this brand and move it for another 3 to 5 years, and how we can build it. Whatever our business plan suggests, then we try to give the multiple accordingly.”

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth1.5x IPM growth; IPM expected at lower double-digit (~10–12%), implying ~15%+ revenue growthNext 3–4 quarters
PAT growth20%FY27
Wokadine CAGR25% CAGR over 3–4 years; next 2 quarters will give more visibility3–4 years
IVF task force PCPMYear-end PCPM of ₹8–9 lakhYear-end (implied FY27)
International FY27 revenueClose at ₹60–₹65 croresFY27 (stated in Q2 FY27 call)
International next-year growth~15% growth on FY27 baseNext year (implied FY28)
New therapy entryEnter nephrology, neuropsychiatry, gastroenterology, spine, rheumatologyWithin 2–3 years (for new therapies generally)
MR addition~150 people possible, not yet decidedSometime in FY28 (conditional)

Key Metrics

MetricQ2 FY27
Revenue₹441 cr, +22.2% YoY
Revenue growth ex-Wokadine21.5% YoY
India business revenue growth22.9% YoY, 97% of total revenue
EBITDA₹96 cr, +22.3% YoY
EBITDA margin21.7%, stable YoY; FY26 full-year was 20.9%
PAT₹60 cr, +15.3% YoY
PAT margin13.7%
H1 FY27 ROCE49.8%
H1 FY27 ROE32.9%
Revenue guidance1.5x IPM growth, implying ~15% revenue growth if IPM grows ~10%
PAT guidance20% growth
MR count3,111, after adding ~400 MRs in Q4 FY26
Engine brands (33) contribution~79% of India business, growing at 22%
CORONA IPM market share0.77%
Core therapies market share~2.3%, growing ~25% faster than IPM
NLEM portfolio contribution~7.5%, down from ~9%
International business revenue₹12.6 cr in Q2, FY27 guidance of ₹60–65 cr
IVF task force PCPM~₹7 lakh in first 6 months, year-end expectation ₹8–9 lakh
Price growth8.9% in Q2, vs historical ~5% from FY23–FY26